Hopewell Pharma Ventures Inc. convinced a federal judge to stay Merck Serono SA’s lawsuit alleging infringement related to its Mavenclad multiple sclerosis treatment after two of the patents were ...

ABSTRACT: Background: This study aimed to evaluate the bioequivalence of the two formulations of metformin 1000 mg XR tablets in healthy male volunteers under fasting conditions. Methods: This was a ...

Dec 23 (Reuters) - Merck (MRK.N), opens new tab will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug Administration's website showed on Monday.

Merck just closed a deal to develop a weight-loss drug. The market appears to think Viking Therapeutics is threatened by that data. There's little reason to write off Viking here. First, let's get ...

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove ...

RAHWAY, N.J., December 20, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for ...

A new evidence-based guideline recommends prescribing metformin when initiating antipsychotic treatment to help mitigate weight gain in certain instances. There is “good evidence” that ...

A nationwide recall of supplements sold for blood sugar support has been announced due to the presence of dangerous drugs prescribed for diabetes. The recall of Fouzee SugarLin Herbal Formula ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...

After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead Sciences' lenacapivir, Merck & Co.'s islatravir is making further strides as a combination treatment with ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...